Hurthle cell tumours of the thyroid. Personal experience and review of the literature
- PMID: 20463834
- PMCID: PMC2868205
Hurthle cell tumours of the thyroid. Personal experience and review of the literature
Abstract
Hurthle cell carcinoma represents about 5% of differentiated thyroid carcinomas. The prognosis of the malignant type of the tumour is still under debate as some Authors have reported that Hurthle cell adenoma occasionally behaves like Hurthle cell carcinoma. Aim of the present study was to evaluate previously reported data and personal experience on the clinical and pathological features of patients affected by Hurthle cell tumour that may predict disease progression and death. In the literature, factors potentially associated with decreased survival were identified and include: age, disease stage, tumour size, extra-glandular invasion, lymph node disease, distant metastases, extensive surgery, radioiodine treatment. From 1992 to 2003, the Authors identified 28 patients affected by Hurthle cell tumour, 9 with Hurthle cell adenoma and 19 with Hurthle cell carcinoma. Of these, 22 were females and 6 males. Mean age of patients affected by adenoma was 49.7 years (range 30-72) vs. 49.3 years (range 15-72) in Hurthle cell carcinoma patients. In all patients, total thyroidectomy was performed. At histology, 9 adenomas, 5 "minimally invasive" and 14 invasive carcinomas were found. Post-operatively, in Hurthle cell carcinoma patients, TNM staging showed 9 patients with stage I, 5 stage II, 4 stage III and one stage IVa (UICC, 2002). All invasive carcinomas underwent (131)I therapy (91-585 mCi). One Hurthle cell carcinoma patient received external beam radiotherapy. The mean follow-up period was 62 months (range 6-324). Relapse was not observed in any of the cases with adenoma. Only one Hurthle cell carcinoma patient showed distant lung metastases at 60 months' follow-up. In conclusion, Hurthle cell carcinoma was not found to present a more aggressive behaviour than follicular carcinoma, when risk factors, including extent of tumour invasion, were taken into account. None of the patients with Hurthle cell adenoma showed a relapse or death caused by the tumour.
Il carcinoma a cellule di Hurthle rappresenta circa il 5% di tutti i carcinomi differenziati della tiroide. La prognosi è ancora oggetto di discussione poiché alcuni Autori hanno riportato che l’adenoma a cellule di Hurthle occasionalmente può mostrare maggiore aggressività, paragonabile a quella del carcinoma. L’obiettivo di questo studio è la valutazione delle caratteristiche cliniche e patologiche predittive di peggior prognosi e di morte per questa neoplasia in un confronto tra i dati riportati in letteratura e la nostra esperienza. In letteratura, i parametri associati a riduzione della sopravvivenza (per tutti i pazienti) sono: età, stadio della malattia, dimensioni del tumore, invasione extraghiandolare, metastasi linfonodali, metastasi a distanza, estensione della chirurgia e terapia con radioiodio. Dal 1992 al 2003 sono stati identificati 28 pazienti affetti da neoplasia a cellule di Hurthle, 9 con adenoma e 19 con carcinoma; di questi 22 erano femmine e 6 maschi. L’età media dei pazienti affetti da adenoma era 49,7 anni (range 30-72) vs. 49,3 anni (range 15-72) dei pazienti affetti da carcinoma a cellule di Hurthle. Tutti i pazienti sono stati sottoposti ad intervento di tiroidectomia totale. L’esame istologico ha evidenziato 9 adenomi e 19 carcinomi di cui 5 minimamente invasivi. La classificazione postoperatoria secondo TNM (UICC, 2002) ha documentato 9 pazienti in stadio I, 5 in stadio II, 4 in stadio III ed 1 in stadio IV. Tutti i 14 carcinomi sono stati sottoposti a terapia con 131I (range 91-585 mCi). Un solo paziente è stato sottoposto a radioterapia esterna. Il follow-up medio è stato di 62 mesi (range 6-324). Nessuno dei pazienti con diagnosi istologica di adenoma ha presentato recidive di malattia. Solo un paziente affetto da carcinoma ha presentato metastasi polmonari dopo 60 mesi di follow-up. In conclusione, l’analisi della nostra casistica, condotta alla luce dei fattori prognostici e predittivi noti in letteratura mostra che il carcinoma a cellule di Hurthle non presenta maggiore aggressività rispetto al carcinoma follicolare, a parità di fattori di rischio incluso l’estensione locale della neoplasia. Nessun paziente affetto da adenoma a cellule di Hurthle ha presentato recidive o è morto a causa della neoplasia.
Keywords: Hurthle cell adenoma; Hurthle cell carcinoma; Thyroid.
Similar articles
-
Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.Cancer. 2003 Mar 1;97(5):1186-94. doi: 10.1002/cncr.11176. Cancer. 2003. PMID: 12599224
-
Hürthle cell carcinoma: a clinicopathological study of thirteen cases.Nucl Med Commun. 2006 Apr;27(4):377-9. doi: 10.1097/01.mnm.0000202862.74917.0c. Nucl Med Commun. 2006. PMID: 16531925
-
Differentiated thyroid carcinomas with vascular invasion: a comparative study of follicular, Hürthle cell and papillary thyroid carcinoma.Pathology. 2002 Jun;34(3):239-44. doi: 10.1080/00313020220131291. Pathology. 2002. PMID: 12109784
-
Hürthle cell tumors of the thyroid gland. Personal experience and review of literature.Anticancer Res. 2002 Nov-Dec;22(6B):3579-82. Anticancer Res. 2002. PMID: 12552959 Review.
-
Recurrent Hurthle cell thyroid carcinoma does not preclude long-term survival: a case report and review of the literature.J Med Case Rep. 2021 Aug 11;15(1):399. doi: 10.1186/s13256-021-02987-z. J Med Case Rep. 2021. PMID: 34376229 Free PMC article. Review.
Cited by
-
Functional polymorphisms in antioxidant genes in Hurthle cell thyroid neoplasm - an association of GPX1 polymorphism and recurrent Hurthle cell thyroid carcinoma.Radiol Oncol. 2016 Jul 19;50(3):289-96. doi: 10.1515/raon-2016-0031. eCollection 2016 Sep 1. Radiol Oncol. 2016. PMID: 27679545 Free PMC article.
-
Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy.Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2526-2535. doi: 10.1007/s00259-019-04456-8. Epub 2019 Aug 13. Eur J Nucl Med Mol Imaging. 2019. PMID: 31410542
-
Rare Occurrence of Incidental Finding of Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features in Hürthle Cell Adenoma.Med Arch. 2018 Nov;72(5):367-370. doi: 10.5455/medarh.2018.72.367-370. Med Arch. 2018. PMID: 30524171 Free PMC article.
-
Thyroid Hürthle cell tumors: research of potential markers of malignancy.J Endocrinol Invest. 2016 Feb;39(2):153-8. doi: 10.1007/s40618-015-0356-x. Epub 2015 Jul 19. J Endocrinol Invest. 2016. PMID: 26188382
-
Immunohistochemical expressions of fatty acid synthase and phosphorylated c-Met in thyroid carcinomas of follicular origin.Int J Clin Exp Pathol. 2011;4(8):755-64. Epub 2011 Oct 30. Int J Clin Exp Pathol. 2011. PMID: 22135723 Free PMC article.
References
-
- Bhattacharyya N. Survival and prognosis in Hurthle cell carcinoma of the thyroid gland. Arch Otolaryngol 2003;129:207-10. - PubMed
-
- Langhans T. Uber die epithelialen Formen der malignen Struma. Virchows Arch (Pathol Anat) 1907;189:69-152.
-
- Har-El G, Hadar T, Segal K, Levy R, Sidi J. Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy. Cancer 1986;57:1613-7. - PubMed
-
- Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Database report on 53856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83:2638-48. - PubMed
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical